PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

This study is using a special PET/CT scan (PSMA-PET/CT) to measure how much of a protein called PSMA is present in triple-negative breast cancer (TNBC) that has progressed or spread. PSMA is a protein usually associated with prostate cancer, but researchers want to know if it also appears in this type of breast cancer, potentially opening new treatment avenues. **You may be eligible if...** - You are a woman aged 18 or older - You have been confirmed to have progressive metastatic triple-negative breast cancer - You have measurable disease on standard imaging - Your general health is acceptable (ECOG 0-2) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had prior PSMA-targeted therapy - You have severe kidney problems preventing contrast dye use Talk to your doctor to see if this trial is right for you.